Several studies, from CRISPR-Cas9 screening to patient-cohort studies, have demonstrated that the loss of function in PBRM1 reduces the resistance of cancer to immune checkpoint inhibitor therapy (Braun et al, 2020; McDermott et al, 2018; Miao et al, 2018; Pan et al, 2018). This evidence concerns the gene PBRM1 and cancer.